Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

Gynecologic Oncology

Volumn 114, Issue 1, 2009, Pages 48-52

  Gershenson, David M ^a   Sun, Charlotte C ^a   Bodurka, Diane ^a   Coleman, Robert L ^a   Lu, Karen H ^a   Sood, Anil K ^a   Deavers, Michael ^a   Malpica, Anais L ^a   Kavanagh, John J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoresistant; Chemotherapy; Low grade; Ovarian cancer

Indexed keywords

ALTRETAMINE; CA 125 ANTIGEN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PLATINUM COMPLEX; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CONTINENTAL POPULATION GROUPS; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; YOUNG ADULT;

EID: 67349236109     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.03.001     Document Type: Article

References (56)

1. Baak J.P., Langley F.A., Talerman A., et al. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal. Quant. Cytol. Histol. 8 4 (1986) 354-357
2. Stalsberg H., Abeler V., Blom G.P., et al. Observer variation in histologic classification of malignant and borderline ovarian tumors. Hum. Pathol. 19 9 (1988) 1030-1035
3. Bichel P., and Jakobsen A. A new histologic grading index in ovarian carcinoma. Int. J. Gynecol. Pathol. 8 2 (1989) 147-155
4. Shimizu Y., Kamoi S., Amada S., et al. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features-problems involved in the architectural grading system. Gynecol. Oncol. 70 1 (1998) 2-12
5. Silverberg S.G. Histopathologic grading of ovarian carcinoma: a review and proposal. Int. J. Gynecol. Pathol. 19 1 (2000) 7-15
6. Malpica A., Deavers M.T., Lu K., et al. Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol. 28 4 (2004) 496-504
7. Malpica A., Deavers M.T., Tornos C., et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am. J. Surg. Pathol. 31 8 (2007) 1168-1174
8. Singer G., Shih Ie M., Truskinovsky A., et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int. J. Gynecol. Pathol. 22 1 (2003) 37-41
9. Singer G., Oldt III R., Cohen Y., et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95 6 (2003) 484-486
10. Singer G., Kurman R.J., Chang H.W., et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am. J. Pathol. 160 4 (2002) 1223-1228
11. Gilks C.B. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int. J. Gynecol. Pathol. 23 3 (2004) 200-205
12. Hsu C.Y., Bristow R., Cha M.S., et al. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin. Cancer Res. 10 19 (2004) 6432-6436
13. Singer G., Stohr R., Cope L., et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol. 29 2 (2005) 218-224
14. Bonome T., Lee J.Y., Park D.C., et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 65 22 (2005) 10602-10612
15. Jazaeri A.A., Lu K., Schmandt R., et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol. Carcinog. 36 2 (2003) 53-59
16. Meinhold-Heerlein I., Bauerschlag D., Hilpert F., et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24 6 (2005) 1053-1065
17. O'Neill C.J., Deavers M.T., Malpica A., et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am. J. Surg. Pathol. 29 8 (2005) 1034-1041
18. Wong K.K., Lu K.H., Malpica A., et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int. J. Gynecol. Pathol. 26 4 (2007) 404-409
19. Gershenson D.M., Sun C.C., Lu K.H., et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet. Gynecol. 108 2 (2006) 361-368
20. Shvartsman H.S., Sun C.C., Bodurka D.C., et al. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol. Oncol. 105 3 (2007) 625-629
21. Schmeler K.M., Sun C.C., Bodurka D.C., et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol. Oncol. 108 3 (2008) 510-514
22. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 3 (2000) 205-216
23. Rustin G.J., Quinn M., Thigpen T., et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J. Natl. Cancer Inst. 96 6 (2004) 487-488
24. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
25. Gore M.E., Fryatt I., Wiltshaw E., et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36 2 (1990) 207-211
26. Markman M., Rothman R., Hakes T., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9 3 (1991) 389-393
27. Dizon D.S., Dupont J., Anderson S., et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol. Oncol. 91 3 (2003) 584-590
28. Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 9375 (2003) 2099-2106
29. Rose P.G., Blessing J.A., Mayer A., et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 16 2 (1998) 405-410
30. Strauss H.G., Henze A., Teichmann A., et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol. Oncol. 104 3 (2007) 612-616
31. Gronlund B., Hogdall C., Hansen H.H., et al. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol. 83 1 (2001) 128-134
32. Markman M., Kennedy A., Webster K., et al. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol. 78 3 Pt 1 (2000) 369-372
33. Gordon A.N., Fleagle J.T., Guthrie D., et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19 14 (2001) 3312-3322
34. Campos S.M., Penson R.T., Mays A.R., et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol. Oncol. 81 2 (2001) 206-212
35. Hensley M.L., Hoppe B., Leon L., et al. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. Gynecol. Oncol. 82 3 (2001) 464-469
36. Gordon A.N., Granai C.O., Rose P.G., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol. 18 17 (2000) 3093-3100
37. Muggia F.M., Hainsworth J.D., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15 3 (1997) 987-993
38. Mutch D.G., Orlando M., Goss T., et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 25 19 (2007) 2811-2818
39. Markman M., Kennedy A., Webster K., et al. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol. Oncol. 79 1 (2000) 116-119
40. Creemers G.J., Bolis G., Gore M., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J. Clin. Oncol. 14 12 (1996) 3056-3061
41. Kudelka A.P., Tresukosol D., Edwards C.L., et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol. 14 5 (1996) 1552-1557
42. Bookman M.A., Malmstrom H., Bolis G., et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16 10 (1998) 3345-3352
43. Bhoola S.M., Coleman R.L., Herzog T., et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol. Oncol. 95 3 (2004) 564-569
44. D'Agostino G., Amant F., Berteloot P., et al. Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. 88 3 (2003) 266-269
45. Brewer C.A., Blessing J.A., Nagourney R.A., et al. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 103 2 (2006) 446-450
46. Markman M., Blessing J., Rubin S.C., et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol. 101 3 (2006) 436-440
47. Le T., Hopkins L., Baines K.A., et al. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecol. Oncol. 102 1 (2006) 49-53
48. Rose P.G., Fusco N., Fluellen L., et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. 16 4 (1998) 1494-1497
49. Hoskins P.J., and Swenerton K.D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 12 1 (1994) 60-63
50. Bajetta E., Di Leo A., Biganzoli L., et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J. Clin. Oncol. 14 (1996) 2546-2551
51. Burger R.A., DiSaia P.J., Roberts J.A., et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol. Oncol. 72 (1999) 148-153
52. Manetta A., Tewari K., Podczaski E.S., et al. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol. Oncol. 66 1 (1997) 20-26
53. Markman M., Blessing J.A., Moore D., et al. Altretamine (Hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol. Oncol. 69 (1998) 226-229
54. Rischin D., Phillips K.A., Friedlander M., et al. A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecol. Oncol. 93 2 (2004) 417-421
55. Wolf J.K., Bodurka D.C., Verschraegen C., et al. A phase II trial of oral capecitabine in patients with platinum- and taxane-refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol. Oncol. 102 3 (2006) 468-474
56. Santillan A., Kim Y.W., Zahurak M.L., et al. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int. J. Gynecol. Cancer 17 (2007) 601-606